Dear Friends and Colleagues,

It is a great pleasure to send you the latest newsletter of the Acute Leukemia Working Party (ALWP) of the EBMT, presenting our current structure and activities, including education, promotion and support to prospective and retrospective clinical trials. We also take the opportunity to invite all EBMT members to design and submit new study proposals as well as to participate in our meetings. The number of HSCT procedures for acute leukemia is continuously increasing, as reflected by growing content of our registry. On one hand, it gives large opportunity to widely investigate various areas of research, on the other, it requires appropriate organization in order to ensure the effectiveness of our work. Currently, over 70 studies are being conducted or discussed. To coordinate such activity, in 2014 we increased the number of subcommittees dedicated to coordinate the studies selection and their conduct. Please, find below their list with respective leaders and their contact addresses.

New study proposals may be submitted in a form of synopsis to the ALWP chairman and appropriate subcommittee leaders. Unfortunately, we cannot guarantee acceptance of all projects. Before approval they must be evaluated for both scientific value and feasibility. These issues may be discussed during our business meetings held twice a year. The upcoming one is planned during the EBMT Meeting in Istanbul, on Monday, 23rd March 2015, between 7:00-9:00 (Room 3B/07). All EBMT members are cordially welcome.

The productivity of the ALWP is huge as reflected by the number of scientific publications and meeting abstracts. Below, please find the list of papers published or accepted in 2014 as well as oral presentations during the ASH 2014 meeting. I would also like to draw your attention to the ALWP papers, which will be presented during the EBMT 2015 meeting and invite you to participate in the ALWP plenary session (33rd March 2015, 13:45–15:15, Harbiye Auditorium).

Apart from the scientific activity, the ALWP is proud of the educational events organized annually in various European countries. The symposia held in Milan 2010 and Warsaw 2011 gave an opportunity for transplanters to meet leaders of the AML and ALL national study groups. Such collaboration appears essential for proper interpretation of our results. Subsequent conferences (Milan 2012, Marseille 2013) reviewed modern trends in pharmacotherapy and immunotherapy. The most recent meeting focused on unrelated donor transplantations took place in Paris on 29th November 2014 and was very well attended (see program below). Additionally, ALWP recently contributed to organization of another conference held in Paris on 30th
January 2015: "Master Classes in Transplantation and Hematology (MATH): A focus on conditioning". Our activity is possible thanks to a collaborative work of all EBMT members who report their data, ALWP data managers (headed by Emmanuelle Polge) and our statistician (Myriam Labopin). We thank you all for your continuous support and wish you brilliant ideas as well as successful, innovative studies.

<table>
<thead>
<tr>
<th>Subcommittee</th>
<th>Leader</th>
<th>e.mail address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute lymphoblastic leukemia</td>
<td>Sebastian Giebel</td>
<td><a href="mailto:sgiebel@io.gliwice.pl">sgiebel@io.gliwice.pl</a></td>
</tr>
<tr>
<td>Alternative donors</td>
<td>Fabio Ciceri</td>
<td><a href="mailto:ciceri.fabio@hsr.it">ciceri.fabio@hsr.it</a></td>
</tr>
<tr>
<td>Autologous SCT</td>
<td>Norbert Claude Gorin</td>
<td><a href="mailto:norbert-claude.gorin@sat.aphp.fr">norbert-claude.gorin@sat.aphp.fr</a></td>
</tr>
<tr>
<td>Cord blood transplantation</td>
<td>Frederic Baron</td>
<td><a href="mailto:f.baron@ulg.ac.be">f.baron@ulg.ac.be</a></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>Christoph Schmid</td>
<td><a href="mailto:christoph.schmid@klinikum-augsburg.de">christoph.schmid@klinikum-augsburg.de</a></td>
</tr>
<tr>
<td>Molecular markers</td>
<td>Jordi Esteve</td>
<td><a href="mailto:jesteve@clinic.ub.es">jesteve@clinic.ub.es</a></td>
</tr>
<tr>
<td>Reduced intensity conditioning</td>
<td>Bipin Savani</td>
<td><a href="mailto:bipin.savani@Vanderbilt.Edu">bipin.savani@Vanderbilt.Edu</a></td>
</tr>
</tbody>
</table>

Chairman
Arnon Nagler
Chaim Sheba Medical Center
Tel-Hashomer, Israel
Email: arnon.nagler@sheba.health.gov.il

Secretary
Sebastian Giebel
Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology
Gliwice, Poland
Email: sgiebel@io.gliwice.pl


ALWP ORAL PRESENTATIONS DURING ASH 2014
(SAN FRANCISCO, December 5-8th)


- Arnon Nagler, et al. RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. Abstract #324.


UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION
FOR ACUTE LEUKEMIA (PARIS, November 29th, 2014)

Session 1 : Donor availability
- Introduction: ALWP chair (Arnon Nagler, Israel) and local host - (Mohamad Mohty, France)
- Availability of unrelated donors: Example of the development of the Polish unrelated donors registry - (Jerzy Holowiecki, Poland)
- HLA and T cells in unrelated transplants: Basic concepts, functional matching - (Katharina Fleischhauer, Germany)
- HLA mis-matching in MUD as a way to reduce relapse? - (Bipin Savani, USA)

Session 2 : Impact of conditioning
- Comparison of sibling donors vs. 10/10 MUD in the standard myeloablative setting - (Ibrahim Yakoub-Agha, France)
- The role of ATG: Optimal dosage and timing? - (Frederic Baron, Belgium)
- Evolution of chemotherapy-based preparative regimens for acute leukemia - (Arnon Nagler, Israel)
- Evolution of radiation-based preparative regimens - (Sebastian Giebel, Poland)

Keynote lecture
Low dose IL-2 for GVHD prevention and therapy? - (David Klatzman, France)

Session 3. Indications for URD-HSCT
- AML - (Jan J. Cornelissen - The Netherlands)
- ALL - (Anthony Goldstone, UK)
- Alternative donors vs. URD-HSCT: haploidentical transplants, cord blood? - (Fabio Ciceri, Italy)
- Autologous HSCT vs. URD-HSCT? - (Norbert-Claude Gorin, France)